Olmutinib in T790M-positive non-small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study.

"Conflict of Interest Disclosures Keunchil Park reports personal fees from Hanmi Pharmaceutical Company, Ltd, during the conduct of the study; grants from MSD Pharmaceuticals, outside the submitted work; and personal fees from AbbVie, Amgen, AstraZeneca, BluePrint Medicines, Bristol‐Myers Squibb, Boehringer‐Ingelheim, Daiichi Sankyo, Eisai, Eli Lilly, JNJ, Merck KGaA, MSD Pharmaceuticals, Puma Biotechnology, and Takeda, outside the submitted work. Pasi A. Jänne reports other support from Hanmi Pharmaceutical Company, Ltd, during the conduct of the study; grants from Boehringer‐Ingelheim, Eli Lilly, Daiichi Sankyo, Takeda Oncology, outside the submitted work; personal fees from AstraZeneca, Boehringer‐Ingelheim, Pfizer, Roche/Genentech, Chugai Pharmaceuticals, Ignyta, Loxo Oncology, Eli Lilly, SFJ Pharmaceuticals, Voronoi, Daiichi Sankyo, Biocartis, Novartis, Sanofi Oncology, Takeda Oncology, Mirati Therapeutics, Transcenta, Silicon Therapeutics, Syndax, Astellas, PUMA, and Revolution Medicines, outside the submitted work; and postmarketing royalties from a Dana‐Farber Cancer Center–owned patent (EGFR Mutations) licensed to Lab Corp. Dong‐Wan Kim reports grants and nonfinancial support from Hanmi Pharmaceutical Company, Ltd, during the conduct of the study; institutional grants from Alpha Biopharm, Amgen, AstraZeneca/Medimmune, Boehringer‐Ingelheim, Daiichi‐Sankyo, Janssen, Meurs, Mirati Therapeutics, MSD Pharmaceuticals, Novartis, Ono Pharmaceutical, Pfizer, Roche/Genentech, Takeda, TP Therapeutics, Xcovery, and Yuhan, outside the submitted work; and nonfinancial support from Amgen and Daiichi‐Sankyo, outside the submitted work. Ji‐Youn Han reports research funding from Ono Pharmaceutical, Pfizer, Roche, and Takeda, outside the submitted work; and personal fees from AstraZeneca, Bristol‐Myers Squibb, MSD Pharmaceuticals, Roche, Eli Lilly, MSD Oncology, Novartis, Pfizer, and Takeda, outside the submitted work. Dae Ho Lee reports personal fees from AbbVie, AstraZeneca, Boehringer‐Ingelheim, Takeda, Bristol‐Myers Squibb, ChongKunDang, CJ Healthcare, Eli Lilly, Janssen, Merck, MSD Pharmaceuticals, Mundipharma, Novartis, Ono Pharmaceutical, Pfizer, Roche, Samyang Biopharm, ST Cube, GreenCross, and Genexine, outside the submitted work. Byoung Chul Cho reports research funding from Novartis, Bayer, AstraZeneca, MOGAM Institute, Dong‐A ST, Champions Oncology, Janssen, Yuhan, Ono Pharmaceutical, Dizal Pharma, MSD Pharmaceuticals, AbbVie, Medpacto, GI Innovation, Eli Lilly, Blueprint Medicines, and Interpark Bio Convergence Corporation, outside the submitted work; personal fees from Novartis, AstraZeneca, Boehringer‐Ingelheim, Roche, Bristol‐Myers Squibb, Ono Pharmaceutical, Yuhan, Pfizer, Eli Lilly, Janssen, Takeda, MSD Pharmaceuticals, Medpacto, Blueprint Medicines, TheraCanVac Inc, Gencurix Inc, Bridgebio Therapeutics, Cyrus Therapeutics, Interpark Bio Convergence Corp, KANAPH Therapeutic Inc, and Guardant Health, outside the submitted work; stock ownership in TheraCanVac Inc, Gencurix Inc, Bridgebio Therapeutics, and KANAPH Therapeutic Inc; is the founder of DAAN Biotherapeutics; receives royalties from Champions Oncology; and is a member the boards of Gencurix Inc and Interpark Bio Convergence Corporation, outside the submitted work. Yong Kek Pang reports other support from Hanmi Pharmaceutical Company, during the course of the study. Enriqueta Felip reports personal fees from AbbVie, Amgen, AstraZeneca, Bayer, Blueprint Medicines, Boehringer‐Ingelheim, Bristol‐Myers Squibb, Eli Lilly, Glaxo‐Smith‐Kline, Janssen, Medscape, Merck KGaA, MSD Pharmaceuticals, Novartis, Roche, Peervoice, Pfizer, Prime Oncology, Puma Biotechnology, Roche, Sanofi Genzyme, Springer, Takeda, and Touchime, outside the submitted work; grants from Grant for Oncology Innovation (GOI) and Fundacion Merck Salud, outside the submitted work; and is an independent member of the board of Grifols. Hyunjin Kim, Eunhye Baek, and Young Su Noh are employees of Hanmi Pharmaceutical Company, Ltd. Ming‐Fang Wu, Jong‐Seok Lee, and Chong‐Jen Yu made no disclosures."

"We thank the patients, their families, and the investigators for participating in this trial. We also thank members of the study team (Hanmi Pharmaceutical Company, Ltd). Professional medical writing assistance was provided, under the guidance of the authors, by David P. Figgitt PhD, ISMPP, CMPP (Content Ed Net), with funding from Hanmi Pharmaceutical Company, Ltd."